Medexus Pharma Q2 revenue misses estimates

Medexus Pharmaceuticals

12/11/2025 23:17

Nov 12 (Reuters) -
Overview

Medexus fiscal Q2 2026 revenue of $24.7 mln missed analyst expectations

Company's adjusted EBITDA decreased due to GRAFAPEX investments and Rupall competition

Gross margin improved to 55.7% from 53.7% year-over-year

Outlook

Medexus expects GRAFAPEX to be accretive to cash flows by fiscal Q3 2026

Company anticipates GRAFAPEX revenue to exceed $100 mln within five years

Result Drivers

GRAFAPEX PERFORMANCE - GRAFAPEX exceeded expectations with strong patient demand since its February 2025 launch, contributing $3.1 mln in Q2 revenue

INVESTMENTS IN GRAFAPEX - Significant investments in GRAFAPEX personnel and infrastructure, totaling $6.0 mln, are expected to be accretive to cash flows by fiscal Q3 2026

RUPALL AND GLEOLAN IMPACT - Revenue decline due to reduced Rupall sales from generic competition and termination of US Gleolan Agreement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$24.74 mln
$25.60 mln (4 Analysts)
Q2 Net Income
-$315,000
Q2 Adjusted EBITDA
$4.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Medexus Pharmaceuticals Inc is C$6.00, about 55% above its November 12 closing price of C$2.70

Press Release: ID:nNFC8yxnTL

For questions concerning the data in this report, contact . For any other questions or feedback, contact .